Best Clean Energy Stocks To Watch For 2015

Best Clean Energy Stocks To Watch For 2015: NeuroMetrix Inc.(NURO)

NeuroMetrix, Inc., a science-based health care company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders, such as those associated with diabetes, carpal tunnel syndrome, lumbosacral disc disease, and spinal stenosis. The company focuses on diagnosis and treatment of the neurological complications of diabetes, including diabetic peripheral neuropathy (DPN) and median neuropathy. Its marketed products include the ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies and invasive electromyography procedures for the diagnosis and evaluation of CTS, low back and leg pain, and DPN; and the NC-stat DPNCheck, a device used to evaluate systemic neuropathies, such as DPN at the point-of-care, as well as consumables and accessories for use with its neurodiagnostic equipment. The company is also developing SENSUS pain therapy device, a transcutaneous electrical nerve stimul ator used in the management of chronic pain, such as that caused by DPN; and ADVANCE CTS, a version of the ADVANCE NCS/EMG device for the detection of CTS in people with diabetes. The company distributes its products directly through its direct sales force and independent sales representatives to physicians, clinics, and hospitals consisting of primary care, internal medicine, orthopedic and hand surgeons, pain medicine physicians, neurologists, physical medicine and rehabilitation, physicians, and neurosurgeons, as well as endocrinology/podiatry market in the United States and internationally. NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts.

Advisors' Opinion:

• [By Bryan Murphy]

  Over the past few weeks, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) and Decision Diagnostics Corp. (OTCBB:DECN) have dominated the diabetes diagnostics and diabetes treatment landscape. Shares of LXRX jumped ! 20% on Tuesday following news that one of the key drugs in its pipeline showed more than enough efficacy in its clinical trials. DECN shares are up more than 250% on the heels of an almost-assured victory in its patent lawsuit against industry giant Johnson & Johnson (NYSE:JNJ). Anyone looking for a new trade in the diabetes diagnostics space, however, may want to look past overbought Lexicon Pharmaceuticals and Decision Diagnostics at this point, and instead turn their attention to newly-budding Neurometrix Inc. (NASDAQ:NURO).

• [By Bryan Murphy]

  For the second time in as many days, I find myself supporting the purchase of a suddenly-bullish stock by saying "this time is different". Yesterday I was talking about OXiGENE Inc. (NASDAQ:OXGN), but today I'm using the term to describe the bullishness that's unfurling with Neurometrix Inc. (NASDAQ:NURO). And just for the record, yes, I know the perils of the "this time is different" argument. I tend to cringe when I hear it, as (too much) experience has taught me that things are rarely different - patterns within the market play themselves out over and over again. In the case of NURO as well as OXGN though, I can put my finger on something specific that we've not yet seen.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/best-clean-energy-stocks-to-watch-for-2015-2.html